Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?
Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher for cytisinicline’s vaping cessation indication investing.com. This rally propelled the shares to multi-month highs in the mid-$3 range. Earlier in the week, ACHV had already begun gaining momentum – on Oct. 15 the stock broke above its 200-day moving average and hit $3.19 marketbeat.com, a bullish technical signal. As of Thursday’s close, the stock was at $3.08, up roughly 10% over the past month and far outperforming the broader market investing.com.
TechStock² Updates
